<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>1366</number>
    <updateDate>2022-12-31T12:17:37Z</updateDate>
    <updateDateIncludingText>2022-12-31T12:17:37Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2021-04-26</introducedDate>
    <congress>117</congress>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2021-04-26T22:07:52Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>United States Pharmaceutical Supply Chain Review Act</title>
        <congress>117</congress>
        <number>1367</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-04-26</actionDate>
          <text>Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Improved Transparency of Foreign Drug Manufacturing Act of 2022</title>
        <congress>117</congress>
        <number>6483</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-01-26</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2021-04-26</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2021-04-26</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>W000817</bioguideId>
        <fullName>Sen. Warren, Elizabeth [D-MA]</fullName>
        <firstName>Elizabeth</firstName>
        <lastName>Warren</lastName>
        <party>D</party>
        <state>MA</state>
        <identifiers>
          <bioguideId>W000817</bioguideId>
        </identifiers>
        <middleName>A.</middleName>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>S001203</bioguideId>
        <fullName>Sen. Smith, Tina [D-MN]</fullName>
        <firstName>Tina</firstName>
        <lastName>Smith</lastName>
        <party>D</party>
        <state>MN</state>
        <identifiers>
          <bioguideId>S001203</bioguideId>
        </identifiers>
        <sponsorshipDate>2021-04-26</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Foreign and international corporations</name>
        </item>
        <item>
          <name>Genetics</name>
        </item>
        <item>
          <name>Government information and archives</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Health care coverage and access</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Industrial policy and productivity</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Public contracts and procurement</name>
        </item>
        <item>
          <name>Retail and wholesale trades</name>
        </item>
        <item>
          <name>Strategic materials and reserves</name>
        </item>
        <item>
          <name>U.S. and foreign investments</name>
        </item>
        <item>
          <name>World health</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2021-04-26</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2021-09-02T20:16:47Z</updateDate>
        <text>
          <![CDATA[ <p><b>Pharmaceutical Supply Chain Defense and Enhancement Act </b></p> <p>This bill requires the Department of Health and Human Services (HHS) to enter into contracts with U.S. entities to manufacture certain critical drugs within the United States.</p> <p>The Food and Drug Administration (FDA) must periodically report to Congress a list of drugs that are critical to public health or national security. The Biomedical Advanced Research and Development Authority within HHS must enter into contracts for qualified U.S. entities to manufacture in the United States the drugs on this list (and ingredients for such drugs). Such contracts must impose certain conditions, such as requiring the manufacturing entity to (1) develop and maintain a redundancy risk management and continuity of business plan, and (2) commit to selling the drugs and ingredients manufactured under the contract at reasonable prices.</p> <p>Beginning in FY2025, certain federal agencies, including the Department of Defense and the Bureau of Prisons, must give priority, in procuring drugs on the FDA critical drugs list, to those that are manufactured in the United States and of high quality. </p> <p>The bill also requires the Federal Trade Commission to submit annually to Congress a report on foreign investment in the U.S. pharmaceutical industry. The report must address, among other topics, the effect of the industry's reliance on foreign manufacturing.</p>]]>
        </text>
      </summary>
    </summaries>
    <title>Pharmaceutical Supply Chain Defense and Enhancement Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Pharmaceutical Supply Chain Defense and Enhancement Act</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to secure the supply of drugs in the United States, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Pharmaceutical Supply Chain Defense and Enhancement Act</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in Senate</type>
        <date>2021-04-26T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s1366is/xml/BILLS-117s1366is.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <date/>
        <formats/>
        <type/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2021-04-26</actionDate>
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
